This drug entry is a stub and has not been fully annotated. It is scheduled to be annotated soon.
Identification
- Generic Name
- Eflapegrastim
- DrugBank Accession Number
- DB15001
- Background
Eflapegrastim is under investigation in clinical trial NCT02953340 (Trial of SPI-2012 Versus Pegfilgrastim in the Management of Chemotherapy Induced Neutropenia in Early- Stage BReast Cancer Patients Receiving Docetaxel and Cyclophosphamide (RECOVER)).
- Type
- Biotech
- Groups
- Investigational
- Synonyms
- Eflapegrastim
Pharmacology
- Indication
Not Available
Reduce drug development failure ratesBuild, train, & validate machine-learning modelswith evidence-based and structured datasets.Build, train, & validate predictive machine-learning models with structured datasets.- Contraindications & Blackbox Warnings
Avoid life-threatening adverse drug eventsImprove clinical decision support with information on contraindications & blackbox warnings, population restrictions, harmful risks, & more.Avoid life-threatening adverse drug events & improve clinical decision support.- Pharmacodynamics
Not Available
- Mechanism of action
- Not Available
- Absorption
Not Available
- Volume of distribution
Not Available
- Protein binding
Not Available
- Metabolism
- Not Available
- Route of elimination
Not Available
- Half-life
Not Available
- Clearance
Not Available
- Adverse Effects
Improve decision support & research outcomesWith structured adverse effects data, including: blackbox warnings, adverse reactions, warning & precautions, & incidence rates.Improve decision support & research outcomes with our structured adverse effects data.- Toxicity
Not Available
- Pathways
- Not Available
- Pharmacogenomic Effects/ADRs
- Not Available
Interactions
- Drug Interactions
- This information should not be interpreted without the help of a healthcare provider. If you believe you are experiencing an interaction, contact a healthcare provider immediately. The absence of an interaction does not necessarily mean no interactions exist.Not Available
- Food Interactions
- Not Available
Categories
- Drug Categories
- Amino Acids, Peptides, and Proteins
- Biological Factors
- Blood Proteins
- Colony-Stimulating Factors
- Cytokines
- Globulins
- Glycoproteins
- Hematopoietic Cell Growth Factors
- Immunoglobulin Constant Regions
- Immunoglobulin Fragments
- Immunoglobulins
- Immunoproteins
- Intercellular Signaling Peptides and Proteins
- Peptide Fragments
- Peptides
- Proteins
- Serum Globulins
- Classification
- Not classified
- Affected organisms
- Not Available
Chemical Identifiers
- UNII
- UT99UG9QJX
- CAS number
- 1384099-30-2
References
- General References
- Not Available
- External Links
- Wikipedia
- Eflapegrastim
Clinical Trials
- Clinical Trials
Phase Status Purpose Conditions Count 3 Completed Treatment Breast Cancer / Neutropenia 2 2 Completed Treatment Neutropenia 1 2 Recruiting Treatment Malignant Lymphomas / Solid Tumors 1 1 Completed Treatment Breast Cancer / Pharmacokinetics 1 1 Recruiting Treatment Breast Cancer / Neutropenia 1
Pharmacoeconomics
- Manufacturers
- Not Available
- Packagers
- Not Available
- Dosage Forms
- Not Available
- Prices
- Not Available
- Patents
- Not Available
Properties
- State
- Not Available
- Experimental Properties
- Not Available
Drug created at May 20, 2019 14:41 / Updated at February 21, 2021 18:55